Phathom Pharmaceuticals

Phathom Pharmaceuticals (Nasdaq: PHAT) is a biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, holding ourselves accountable to be equitable and just, and authentically supporting the people and communities impacted by our work, we strive to create a sense of inclusion and belonging. We are looking for self-motivated, creative problem solvers who are excited by the idea of working in a fast-paced start-up environment and contributing to our growth.

Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

Singular Genomics

Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. We are a publicly traded life science technology company that is leveraging novel, next-generation sequencing (NGS) and multi-omics technologies to build products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. We are committed to unlocking the potential of our core technologies to reshape the future of genomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact in a rapidly expanding company. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.

icon government and public health solutions

ICON Government and Public Health Solutions, ICON GPHS provides full-service clinical development and staffing services across multiple agencies in the US Government and is a trusted partner to both multinational public health organizations, and global Non-Government Organizations (NGOs). Our clinical development expertise extends across basic and applied research, manufacturing, infectious and neglected tropical diseases, oncology, vaccines development and testing, and the response to bio-threats.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.